Anixa Biosciences Inc (ANIX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $91.08M
Last updated: Nov 17, 2026 at 11:04 AM ET
Anixa Biosciences Inc (ANIX) Competitors
The companies most similar to Anixa Biosciences are XBiotech (XBIT), Immunic (IMUX) and Codexis (CDXS). By market cap, Anixa Biosciences ranks 6th of the 13 companies on this page; Atrium Therapeutics, Inc. Common Stock (RNA) is the largest at $162.00M.
Peer Comparison
ANIX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Anixa Biosciences (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| XBiotech Inc (XBIT) | $59.76M | N/A | N/A | 0.0% | N/A | -93.3% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Codexis Inc (CDXS) | $127.13M | N/A | N/A | -21.8% | N/A | 124.0% | 0.00% |
| Atrium Therapeutics, Inc. Common Stock (RNA) | $162.00M | N/A | 3.3x | -180.9% | -44.5% | 24.2% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| Champions Oncology Inc (CSBR) | $65.49M | N/A | 1.0x | -1.9% | N/A | 8.8% | 0.00% |
| MAIA Biotechnology Inc. (MAIA) | $61.75M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tenax Therapeutics Inc (TENX) | $73.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Nkarta Inc (NKTX) | $85.23M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| MacroGenics Inc (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $83.22M | N/A | 2.4x | 0.0% | -76.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Anixa Biosciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| XBiotech Inc (XBIT) | XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. | XBIT competitors |
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| Codexis Inc (CDXS) | Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California. | CDXS competitors |
| Atrium Therapeutics, Inc. Common Stock (RNA) | Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. | RNA competitors |
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| Champions Oncology Inc (CSBR) | Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. | CSBR competitors |
| MAIA Biotechnology Inc. (MAIA) | MAIA Biotechnology Inc. is an innovative biotechnology company focused on developing cutting-edge cancer therapies that significantly improve patient outcomes... | MAIA competitors |
| Tenax Therapeutics Inc (TENX) | Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing... | TENX competitors |
| Nkarta Inc (NKTX) | Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. | NKTX competitors |
| MacroGenics Inc (MGNX) | MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. | MGNX competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| ImageneBio, Inc. (IMA) | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
Frequently Asked Questions About ANIX
Who are Anixa Biosciences' main competitors?
The companies most similar to Anixa Biosciences include XBiotech (XBIT), Immunic (IMUX), Codexis (CDXS), Atrium Therapeutics, Inc. Common Stock (RNA) and Coherus BioSciences (CHRS), listed from the closest match.
Who is Anixa Biosciences' biggest competitor?
Atrium Therapeutics, Inc. Common Stock (RNA) is the largest of the similar companies at $162.00M; XBiotech (XBIT) is the closest match by business profile, size, sector and industry.
How does ANIX stock compare with its competitors?
ANIX's net margin is 0.0% against a peer median of 0.0%.
Which of Anixa Biosciences' competitors pays a higher dividend?
Anixa Biosciences pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Anixa Biosciences bigger than its competitors?
No. Anixa Biosciences is 6th by market cap among the 13 companies on this page; the largest is Atrium Therapeutics, Inc. Common Stock (RNA) at $162.00M.
ANIX pages: Overview, Earnings, Forecast, Financials, Competitors